Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Lung Cancer

Free Subscription 13.05.2024 7 Ann Surg Oncol 1 Arch Bronconeumol 2 BMC Cancer 3 Cancer 1 Cancer Lett 3 Chest 5 Clin Lung Cancer 4 Clin Nucl Med 1 Eur J Cardiothorac Surg 1 Hum Pathol 1 J Cancer Res Clin Oncol 1 J Immunol 1 J Thorac Cardiovasc Surg 11 J Thorac Oncol 7 Lung Cancer 1 Mol Carcinog 2 PLoS Genet 3 PLoS One 2 Thorax

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Surg Oncol

1. DENG HY, Zhou Q
   Pleural Invasion in Non-small Cell Lung Cancer: An Important Characteristic during Clinical Decision-Making.
   Ann Surg Oncol. 2024 May 8. doi: 10.1245/s10434-024-15401.
   PubMed        
   
   
2. ISHIDA M, Mimae T, Okada M
   ASO Author Reflections: How Does Emphysema Contribute to Poor Prognosis After Lung Cancer Surgery?
   Ann Surg Oncol. 2024 May 8. doi: 10.1245/s10434-024-15171.
   PubMed        
   
   
3. APRILE V, Ambrogi MC, Lucchi M
   Surgery in Stage IV Non-small Cell Lung Cancer: Good Time for a Chance.
   Ann Surg Oncol. 2024 May 6. doi: 10.1245/s10434-024-15308.
   PubMed        
   
   
4. YAN HJ, Zhao JS, Liu Q, Yang C, et al
   ASO Author Reflections: The Clinical Use of Dual-Region Radiomics-Based Machine Learning in the Identification of Subcarinal Lymph Node Metastasis of Non-small Cell Lung Cancer.
   Ann Surg Oncol. 2024 May 6. doi: 10.1245/s10434-024-15271.
   PubMed        
   
   
5. BANSAL VV, Mitchell O, Drazer MW, Kindler HL, et al
   ASO Author Reflections: Venous Thromboembolism in Peritoneal Mesothelioma.
   Ann Surg Oncol. 2024;31:3785-3786.
   PubMed        
   
   
6. KOTI S, Demyan L, Deutsch G, Weiss M, et al
   Surgery for Oligometastatic Pancreatic Cancer: Defining Biologic Resectability.
   Ann Surg Oncol. 2024;31:4031-4041.
   PubMed         Abstract available
   
   
7. SHARMA J, Deo SVS, Kumar S, Bhoriwal S, et al
   Malignant Chest Wall Tumors: Complex Defects and Their Management-A Review of 181 Cases.
   Ann Surg Oncol. 2024;31:3675-3683.
   PubMed         Abstract available
   
   

   
   Arch Bronconeumol

8. CARDENAL BD, Serra-Mitja P
   A Rare Pulmonary Metastasis of Uveal Melanoma Diagnosed Through Endobronchial Endosonography and Fine Needle Aspiration: A Case Report.
   Arch Bronconeumol. 2024;60:298-299.
   PubMed        
   
   

   
   BMC Cancer

9. WANG M, Jing X, Chen F, Lu S, et al
   Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with driver-gene negative advanced non-small cell lung cancer.
   BMC Cancer. 2024;24:569.
   PubMed         Abstract available
   
   
10. XIA L, Lin H, Cao H, Lian J, et al
    Tenascin C as a novel zinc finger protein 750 target regulating the immunogenicity via DNA damage in lung squamous cell carcinoma.
    BMC Cancer. 2024;24:561.
    PubMed         Abstract available
    
    

    
    Cancer

11. YOUNG LK, Halmos B
    Immunotherapy for metastatic non-small cell lung cancer: Is it really a no-brainer?
    Cancer. 2024 May 6. doi: 10.1002/cncr.35350.
    PubMed        
    
    
12. LEAL TA, Ramalingam SS
    Commemorating the 20th anniversary of the discovery of epidermal growth factor receptor mutation in lung cancer: Translational research at its best.
    Cancer. 2024 May 8. doi: 10.1002/cncr.35353.
    PubMed        
    
    
13. AREDO JV, Wakelee HA
    Top advances of the year: Perioperative therapy for lung cancer.
    Cancer. 2024 May 8. doi: 10.1002/cncr.35357.
    PubMed         Abstract available
    
    

    
    Cancer Lett

14. CHEN X, Yuan M, Zhong T, Wang M, et al
    LILRB2 Inhibition Enhances Radiation Sensitivity in Non-Small Cell Lung Cancer by Attenuating Radiation-Induced Senescence.
    Cancer Lett. 2024 May 3:216930. doi: 10.1016/j.canlet.2024.216930.
    PubMed         Abstract available
    
    

    
    Chest

15. VARONE F, Martini A, Cicchetti G, Iovene B, et al
    Case of a 33-Year-Old Woman With Hemoptysis and Migrant Nodular Cavitary Lesions.
    Chest. 2024;165:e133-e136.
    PubMed         Abstract available
    
    
16. ARENBERG D
    Treating Lung Metastases: More Evidence for Equipoise.
    Chest. 2024;165:1037-1038.
    PubMed        
    
    
17. GITS HC, Khosravi Flanigan MA, Kapplinger JD, Reisenauer JS, et al
    Sublobar Resection, Stereotactic Body Radiation Therapy, and Percutaneous Ablation Provide Comparable Outcomes for Lung Metastasis-Directed Therapy.
    Chest. 2024;165:1247-1259.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

18. MILLS MN, Uno A, Li P, Liveringhouse C, et al
    Clinical Outcomes of Patients with Non-Small Cell Lung Cancer Leptomeningeal Disease Following Receipt of EGFR-Targeted Therapy, Immune-Checkpoint Blockade, Intrathecal Chemotherapy, or Radiation Therapy Alone.
    Clin Lung Cancer. 2024 Apr 10:S1525-7304(24)00048.
    PubMed         Abstract available
    
    
19. FANTONI A, Warburton L, Solomon B, Alexander M, et al
    Completion of Pembrolizumab in Advanced Non-Small Cell Lung Cancer-Real World Outcomes After Two Years of Therapy (COPILOT).
    Clin Lung Cancer. 2024 Apr 15:S1525-7304(24)00051.
    PubMed         Abstract available
    
    
20. ORDING AG, Christensen TD, Skjoth F, Noble S, et al
    Risk of Venous Thromboembolism in Patients With Stage III and IV Non-Small-Cell Lung Cancer: Nationwide Descriptive Cohort Study.
    Clin Lung Cancer. 2024 Apr 11:S1525-7304(24)00047.
    PubMed         Abstract available
    
    
21. PAN H, Chen H, Kong W, Ning J, et al
    Video-Assisted Thoracoscopic Surgery Versus Thoracotomy Following Neoadjuvant Immunochemotherapy in Resectable Stage III Non-Small Cell Lung Cancer Among Chinese Populations: A Multi-Center Retrospective Cohort Study.
    Clin Lung Cancer. 2024 Apr 2:S1525-7304(24)00042.
    PubMed         Abstract available
    
    
22. JIANG Z, Li Q, Ruan J, Li Y, et al
    Machine Learning-Based Prediction of Pathological Responses and Prognosis After Neoadjuvant Chemotherapy for Non-Small-Cell Lung Cancer: A Retrospective Study.
    Clin Lung Cancer. 2024 Apr 12:S1525-7304(24)00049.
    PubMed         Abstract available
    
    

    
    Clin Nucl Med

23. YANG H, Liu H, Zhang Y, Zhang Y, et al
    Metastatic Lung Adenocarcinoma Received Combined 177 Lu-FAP-2286 Radiation Therapy and Targeted Therapy.
    Clin Nucl Med. 2024;49:569-571.
    PubMed         Abstract available
    
    
24. LIANG S, Chen X
    Solitary Pulmonary Perivascular Epithelial Cell Tumor Mimicking Pulmonary Metastasis on 68Ga-DOTATATE PET/CT in a Patient With Pancreatic Neuroendocrine Tumor.
    Clin Nucl Med. 2024 Apr 17. doi: 10.1097/RLU.0000000000005235.
    PubMed         Abstract available
    
    
25. ZHANG J, Dong A, Wang Y
    FDG PET/CT in a Case of Solitary Mixed Squamous Cell and Glandular Papilloma of the Lung With High CEA Level.
    Clin Nucl Med. 2024;49:e288-e289.
    PubMed         Abstract available
    
    
26. PUROHIT P, Mittal BR, Kumar R, Singh H, et al
    68Ga-FAPI PET/CT in an Interesting Case of Metastatic Pulmonary Meningioma.
    Clin Nucl Med. 2024 Mar 25. doi: 10.1097/RLU.0000000000005161.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

27. LEE M, Santhirakumaran G, Waller D, Elkhouly A, et al
    The use of diagnostic complex robotic-assisted segmentectomy in the management of incidental and screen-detected pulmonary nodules.
    Eur J Cardiothorac Surg. 2024;65:ezae139.
    PubMed         Abstract available
    
    

    
    Hum Pathol

28. NASO JR, Wang D, Romero AO, Leclair T, et al
    Pulmonary gangliocytic paraganglioma: An under-recognized mimic of carcinoid tumor.
    Hum Pathol. 2024;146:23-27.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

29. LI R, Tong R, Zhang JL, Zhang Z, et al
    Comprehensive molecular analyses of cuproptosis-related genes with regard to prognosis, immune landscape, and response to immune checkpoint blockers in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2024;150:246.
    PubMed         Abstract available
    
    

    
    J Immunol

30. SAXENA R, Bushey RT, Campa MJ, Gottlin EB, et al
    Promotion of an Antitumor Immune Program by a Tumor-specific, Complement-activating Antibody.
    J Immunol. 2024;212:1589-1601.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

31. HSU DS, Kneuertz PJ
    Commentary: "HIIT"ing the Jackpot with Prehabilitation before Minimally Invasive Lung Cancer Surgery.
    J Thorac Cardiovasc Surg. 2024 May 3:S0022-5223(24)00374.
    PubMed        
    
    

    
    J Thorac Oncol

32. OU SI, Hagopian GG, Zhang SS, Nagasaka M, et al
    Comprehensive Review of ROS1 Tyrosine Kinase Inhibitors-Classified by Structural Designs and Mutation Spectrum (Solvent Front Mutation [G2032R] and Central beta-Sheet 6 [Cbeta6] Mutation [L2086F]).
    J Thorac Oncol. 2024;19:706-718.
    PubMed         Abstract available
    
    
33. LUO J, Sanchez M, Lee E, Hertzler H, et al
    Initial Chemotherapy for Locally Advanced and Metastatic NUT Carcinoma.
    J Thorac Oncol. 2024;19:829-838.
    PubMed         Abstract available
    
    
34. WOODARD GA, Dacic S
    Should the TNM Staging of NSCLC Evolve Beyond Anatomical Descriptors?
    J Thorac Oncol. 2024;19:663-665.
    PubMed        
    
    
35. ISHIKAWA S
    Artificial Intelligence Enhances NSCLC Care by Predicting Treatment Outcomes, Validating Neoadjuvant Therapies, and Improving Precision.
    J Thorac Oncol. 2024;19:666-667.
    PubMed        
    
    
36. SHIH JY
    ERBB2 Amplification in NSCLC: How Many Faces?
    J Thorac Oncol. 2024;19:668-670.
    PubMed        
    
    
37. BLAAUWGEERS H, Dickhoff C, Pelosi G, Timens W, et al
    Con: "Is Spread Through Air Spaces an In Vivo Phenomenon or an Inducible Artifact?".
    J Thorac Oncol. 2024;19:671-676.
    PubMed        
    
    
38. LI Y, Adusumilli PS, Chou TY, Kadota K, et al
    Pro: "Is Spread Through Air Spaces an In Vivo Phenomenon or an Inducible Artifact?".
    J Thorac Oncol. 2024;19:677-697.
    PubMed         Abstract available
    
    
39. SRINIVASALU VK, Patnaik RS, Kiong LS, Justin JS, et al
    Lung Cancer in Brunei Darussalam.
    J Thorac Oncol. 2024;19:698-705.
    PubMed        
    
    
40. ZHAO B, Yao L, Ma W
    Osimertinib Versus Durvalumab Versus Observation After Chemoradiation in Unresectable EGFR-Mutant NSCLC.
    J Thorac Oncol. 2024;19:e5-e6.
    PubMed        
    
    
41. CHEN CY, Wang GS, Wei JC
    Comment on "Consolidation Osimertinib Versus Durvalumab following Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC".
    J Thorac Oncol. 2024;19:e6-e7.
    PubMed        
    
    
42. NASSAR AH, Kim SY, Adib E, Naqash AR, et al
    Response letter by Nassar et al.
    J Thorac Oncol. 2024;19:e7-e8.
    PubMed        
    
    

    
    Lung Cancer

43. WANG L, Li L, Zhou X, Zhang D, et al
    Identification of a novel ALK inhibitor-sensitive PRKCE-ALK gene fusion in lung adenocarcinoma.
    Lung Cancer. 2024;191:107797.
    PubMed        
    
    
44. LU YF, Chang YH, Chen YJ, Hsieh MS, et al
    Proteomic profiling of tumor microenvironment and prognosis risk prediction in stage I lung adenocarcinoma.
    Lung Cancer. 2024;191:107791.
    PubMed         Abstract available
    
    
45. CHOUR A, Basse C, Lebosse F, Bonte PE, et al
    Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal.
    Lung Cancer. 2024;191:107789.
    PubMed         Abstract available
    
    
46. MIYAKOSHI J, Yoshida T, Kashima J, Shirasawa M, et al
    Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression.
    Lung Cancer. 2024;191:107788.
    PubMed         Abstract available
    
    
47. NISHIMURA T, Fujimoto H
    Is the onset of immune-related adverse events themselves a prognostic factor or a confounding factor?
    Lung Cancer. 2024;191:107561.
    PubMed        
    
    
48. HOCKING AJ, Mortimer LA, Farrall AL, Russell PA, et al
    Establishing mesothelioma patient-derived organoid models from malignant pleural effusions.
    Lung Cancer. 2024;191:107542.
    PubMed         Abstract available
    
    
49. LIU G, Mazieres J, Stratmann J, Ou SI, et al
    A pragmatic guide for management of adverse events associated with lorlatinib.
    Lung Cancer. 2024;191:107535.
    PubMed         Abstract available
    
    

    
    Mol Carcinog

50. CHEN C, Tang D, Xu S, Xiang L, et al
    The promotion of non-small cell lung cancer progression by collagen and calcium binding EGF domain 1 is mediated through the regulation of ERK/JNK/P38 phosphorylation by reactive oxygen species.
    Mol Carcinog. 2024 May 10. doi: 10.1002/mc.23736.
    PubMed         Abstract available
    
    

    
    PLoS Genet

51. MAJOCHA MR, Jackson DE, Ha NH, Amin R, et al
    Resf1 is a compound G4 quadruplex-associated tumor suppressor for triple negative breast cancer.
    PLoS Genet. 2024;20:e1011236.
    PubMed         Abstract available
    
    
52. 
    Retraction: miR-3607-3p suppresses non-small cell lung cancer (NSCLC) by targeting TGFBR1 and CCNE2.
    PLoS Genet. 2024;20:e1011270.
    PubMed        
    
    

    
    PLoS One

53. HUH Y, Sohn YJ, Kim HR, Chun H, et al
    Sex differences in prognosis factors in patients with lung cancer: A nationwide retrospective cohort study in Korea.
    PLoS One. 2024;19:e0300389.
    PubMed         Abstract available
    
    
54. BAK SH, Park J, Lee S, Kim JH, et al
    Clinical usability of 3D gradient-echo-based ultrashort echo time imaging: Is it enough to facilitate diagnostic decision in real-world practice?
    PLoS One. 2024;19:e0296696.
    PubMed         Abstract available
    
    
55. HAN KT, Kim S
    Does improved nurse staffing impact patient outcomes in cancer? Association between chronic diseases and mortality among older adult patients with lung cancer in Korea.
    PLoS One. 2024;19:e0301010.
    PubMed         Abstract available
    
    

    
    Thorax

56. RAHMAN ML, Breeze CE, Shu XO, Wong JYY, et al
    Epigenome-wide association study of lung cancer among never smokers in two prospective cohorts in Shanghai, China.
    Thorax. 2024 May 3:thorax-2023-220352. doi: 10.1136/thorax-2023-220352.
    PubMed         Abstract available
    
    
57. CHRISTIANI DC
    Epigenetic clock as the new hand of time for lung cancer in never smokers.
    Thorax. 2024 May 3:thorax-2024-221393. doi: 10.1136/thorax-2024-221393.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.